Celltrion Healthcare Inc. planted the oncology flag in biosimilars with the European Commission's approval of Truxima, a biosimilar to Rituxan (rituximab, Roche Holding AG/Biogen Inc.), and the compound will provide estimated health care savings across the 28 countries of the EU of about €570 million (US$602 million) over a three-year period.